Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition - Disaggregation of Revenue (Details)

v3.21.1
Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Disaggregation of Revenue [Line Items]    
Total revenues $ 18,032 $ 14,670
Americas [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues 4,929 5,225
EMEA [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues 6,282 5,971
APAC [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues 6,821 3,474
Product Revenue [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues 10,226 5,100
Research and Development Revenue [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues 7,806 9,570
Performance Enzymes [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues 14,229 10,874
Performance Enzymes [Member] | Americas [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues 2,871 2,999
Performance Enzymes [Member] | EMEA [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues 4,537 4,401
Performance Enzymes [Member] | APAC [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues 6,821 3,474
Performance Enzymes [Member] | Product Revenue [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues 10,226 5,100
Performance Enzymes [Member] | Research and Development Revenue [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues 4,003 5,774
Novel Biotherapeutics [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues 3,803 3,796
Novel Biotherapeutics [Member] | Americas [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues 2,058 2,226
Novel Biotherapeutics [Member] | EMEA [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues 1,745 1,570
Novel Biotherapeutics [Member] | APAC [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues 0 0
Novel Biotherapeutics [Member] | Product Revenue [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues 0 0
Novel Biotherapeutics [Member] | Research and Development Revenue [Member]    
Disaggregation of Revenue [Line Items]    
Total revenues $ 3,803 $ 3,796